Drugs for Alcohol Use Disorder
December 13, 2021 (Issue: 1639)
Consumption of alcohol has increased during the
COVID-19 pandemic. The Diagnostic and Statistical
Manual for Mental Disorders, 5th edition (DSM-5) defines
alcohol use disorder (AUD; previously called alcohol
dependence) as meeting ≥2 of the 11...more
- BF Grant et al. Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry 2015; 72:757.
- K Witkiewitz et al. Advances in the science and treatment of alcohol use disorder. Sci Adv 2019; 5:eaax4043.
- VI Reus et al. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry 2018; 175:86.
- U.S. Department of Veterans Affairs. VA/DoD clinical practice guideline for the management of substance use disorders. Version 4.0 – 2021. Available at: https://bit.ly/3CkSSEp. Accessed November 18, 2021.
- HR Kranzler and M Soyka. Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA 2018; 320:815.
- Naltrexone for alcohol dependence. Med Lett Drugs Ther 1995; 37:64.
- Naltrexone (Vivitrol) – a once monthly injection for alcoholism. Med Lett Drugs Ther 2006; 48:62.
- Drugs for opioid use disorder. Med Lett Drugs Ther 2017; 59:89.
- S Rösner et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010; 12:CD001867.
- RF Anton et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295:2003.
- JR Volpicelli et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49:876.
- JR Volpicelli et al. Effect of naltrexone on alcohol "high" in alcoholics. Am J Psychiatry 1995; 152:613.
- JC Garbutt et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005; 293:1617.
- Drug Interactions from The Medical Letter. Available at: www.medicalletter.org/subDIO.
- GP Overman et al. Acamprosate for the adjunctive treatment of alcohol dependence. Ann Pharmacother 2003; 37:1090.
- BJ Mason and P Lehert. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcohol Clin Exp Res 2012; 36:497.
- DE Jonas et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA 2014; 311:1889.
- MD Skinner et al. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One 2014; 9: e87366.
- JC Blodgett et al. A meta-analysis of topiramate’s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res 2014; 38:1481.
- G Martinotti et al. Low-dose topiramate in alcohol dependence: a single-blind, placebo-controlled study. J Clin Psychopharmacol 2014; 34:709.
- A Manhapra et al. Topiramate pharmacotherapy for alcohol use disorder and other addictions: a narrative review. J Addict Med 2019; 13:7.
- BJ Mason et al. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med 2014; 174:70.
- RF Anton et al. Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial. JAMA Intern Med 2020; 180:728.
- DE Falk et al. Gabapentin enacarbil extended-release for alcohol use disorder: a randomized, double-blind, placebo-controlled, multisite trial assessing efficacy and safety. Alcohol Clin Exp Res 2019; 43:158.
- EM Laska et al. Gabapentin encarbil extended-release versus placebo: a likely responder reanalysis of a randomized clinical trial. Alcohol Clin Exp Res 2020; 44:1875.
- JC Garbutt et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial. Neuropsychopharmacology 2021; 46:2250.
- S Minozzi et al. Baclofen for alcohol use disorder. Cochrane Database Syst Rev 2018; 11:CD012557.
- C Chaignot et al. Risk of hospitalisation and death related to baclofen for alcohol use disorders: comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France. Pharmacoepidemiol Drug Saf 2018; 27:1239.
- TL Simpson et al. Double-blind randomized clinical trial of prazosin for alcohol use disorder. Am J Psychiatry 2018; 175:1216.
- SS O’Malley et al. Effect of varenicline combined with medical management on alcohol use disorder with comorbid cigarette smoking: a randomized clinical trial. JAMA Psychiatry 2018; 75:129.
- HM Pettinati et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry 2010; 167:668.
- HR Kranzler et al. Post-treatment effects of topiramate treatment for heavy drinking. Alcohol Clin Exp Res 2014; 38:3017.
- E Kelty et al. Prevalence and safety of acamprosate use in pregnant alcohol-dependent women in New South Wales, Australia. Addiction 2019; 114:206.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
